Publicaciones en las que colabora con Begoña López Salazar (128)

2024

  1. Circulating biomarkers of myocardial remodelling: current developments and clinical applications

    Heart, Vol. 110, Núm. 19, pp. 1157-1163

  2. Myocardial Interstitial Fibrosis in Hypertensive Heart Disease: From Mechanisms to Clinical Management

    Hypertension, Vol. 81, Núm. 2, pp. 218-228

2022

  1. A Fibrosis Biomarker Early Predicts Cardiotoxicity Due to Anthracycline-Based Breast Cancer Chemotherapy

    Cancers, Vol. 14, Núm. 12

  2. Biomarker-based assessment of collagen cross-linking identifies patients at risk of heart failure more likely to benefit from spironolactone effects on left atrial remodelling. Insights from the HOMAGE clinical trial

    European Journal of Heart Failure, Vol. 24, Núm. 2, pp. 321-331

  3. Heart failure in chronic kidney disease: The emerging role of myocardial fibrosis

    Nephrology Dialysis Transplantation, Vol. 37, Núm. 5, pp. 817-824

2021

  1. Diffuse myocardial fibrosis: mechanisms, diagnosis and therapeutic approaches

    Nature Reviews Cardiology, Vol. 18, Núm. 7, pp. 479-498

  2. Galectin-3 Inhibition With Modified Citrus Pectin in Hypertension

    JACC: Basic to Translational Science, Vol. 6, Núm. 1, pp. 12-21

2020

  1. Author Correction: MicroRNA-19b is a potential biomarker of increased myocardial collagen cross-linking in patients with aortic stenosis and heart failure (Scientific Reports, (2017), 7, 1, (40696), 10.1038/srep40696)

    Scientific Reports

  2. Burden and challenges of heart failure in patients with chronic kidney disease. A call to action

    Nefrologia, Vol. 40, Núm. 3, pp. 223-236

  3. Cardiac magnetic resonance-derived fibrosis, strain and molecular biomarkers of fibrosis in hypertensive heart disease

    Journal of hypertension, Vol. 38, Núm. 10, pp. 2036-2042

  4. Cardiorenal interaction and heart failure outcomes. A role for insulin-like growth factor binding protein 2?

    Revista Espanola de Cardiologia, Vol. 73, Núm. 10, pp. 835-843

  5. Does chronic kidney disease facilitate malignant myocardial fibrosis in heart failure with preserved ejection fraction of hypertensive origin?

    Journal of Clinical Medicine, Vol. 9, Núm. 2

  6. Hypertrophic cardiomyopathy in myosin-binding protein C (MYBPC3) Icelandic founder mutation carriers

    Open Heart, Vol. 7, Núm. 1

  7. Natural Compound Library Screening Identifies New Molecules for the Treatment of Cardiac Fibrosis and Diastolic Dysfunction

    Circulation, Vol. 141, Núm. 9, pp. 751-767

  8. Reprint of “The complex dynamics of myocardial interstitial fibrosis in heart failure. Focus on collagen cross-linking”

    Biochimica et Biophysica Acta - Molecular Cell Research, Vol. 1867, Núm. 3

2019

  1. Association of left atrium voltage amplitude and distribution with the risk of atrial fibrillation recurrence and evolution after pulmonary vein isolation: An ultrahigh-density mapping study

    Journal of Cardiovascular Electrophysiology, Vol. 30, Núm. 8, pp. 1231-1240

  2. CT-1 (Cardiotrophin-1)-Gal-3 (Galectin-3) axis in cardiac fibrosis and inflammation: Mechanistic insights and clinical implications

    Hypertension, Vol. 73, Núm. 3, pp. 602-611

  3. Cardioprotective Effect of the Mitochondrial Unfolded Protein Response During Chronic Pressure Overload

    Journal of the American College of Cardiology, Vol. 73, Núm. 14, pp. 1795-1806

  4. Circulating biomarkers predicting longitudinal changes in left ventricular structure and function in a general population

    Journal of the American Heart Association, Vol. 8, Núm. 2

  5. Circulating long noncoding RNA LIPCAR Predicts heart failure outcomes in patients without chronic kidney disease

    Hypertension, Vol. 73, Núm. 4, pp. 820-828